Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

Another notable valuation metric for GMED is its P/B ratio of 2.85. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus ...

you should consider Globus Medical (GMED). This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat. This medical device company has seen a ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...